Text Link
Nov 24, 2021

Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1

We are proud and overjoyed, the hard work of the ARTHEx’s team has earned recognition after our first-anniversary celebration. This month has been fascinating, bringing us several grants and awards at regional, national, and international levels.

The €250K funding from the Neotec program has been a resounding success. Indeed, this is the most prestigious grant for technology-based start-ups in Spain. Neotec is managed by CDTI, the governmental organism of the Spanish Ministry of Science dedicated to boost industrial R&D.

Moreover, Arthex has won additional funding from the HeadStart program of EIT Health (the network of best-in-class health innovators backed by the European Union). Participating in the second phase of the program will allow us to assess our research in samples from DM1 patients, thanks to a new collaboration with Dr. Gisela Nogales at IGTP (Badalona, Spain).

Last but not least, ARTHEx has been awarded during this month as one of the best start-ups at the regional level. ARTHEx has won the third award as the most innovative spin-off from the public universities of the Valencian Region (5UCV Startup program), has been a finalist of the contest for Biotech Startups organized by Bioval (Valencian cluster of biotechnology), and has been awarded by the VLC STARTUP CALL of the Science Park of the University of Valencia. This last award includes a new office at the Park that we look forward to opening.

“We are extremely grateful for the full confidence of all these organizations, and hopefully, with their support, we will advance in the development of a therapy for patients suffering from myotonic dystrophy”, says Dr. Beatriz Llamusi, ARTHEx’s CEO and co-founder.

Continue reading